Naiyer A. Rizvi
Yale New Haven Hospital
4 papers in the Anchorcite directory, published between 2013 and 2015, cited 27,972 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 4 papers
- Lung Cancer Treatments and Mutations · 3 papers
- Lung Cancer Diagnosis and Treatment · 1 paper
- Cancer Genomics and Diagnostics · 1 paper
- Lung Cancer Research Studies · 1 paper
- Immunotherapy and Immune Responses · 1 paper
Frequent co-authors
- Leora Horn · 2 papers
- Enriqueta Felip · 2 papers
- Matthew David Hellmann · 2 papers
- Edward B. Garon · 2 papers
- Jedd D. Wolchok · 2 papers
- Hossein Borghaei · 1 paper
- Luis G Paz-Ares · 1 paper
- David Robert Spigel · 1 paper
Papers
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 9,473 citations
BACKGROUND: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had…
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience · 2015 · 7,918 citations
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, we used whole-exome sequencing of non-small cell lung cancers treated with pembrolizumab, an…
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations
BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of…
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2013 · 4,287 citations
BACKGROUND: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis…
Metadata from OpenAlex (CC0).